FeesSafety
Pluang+

Class action lawsuit filed against EyePoint over alleged false claims about DURAVYU drug effectiveness.

Market News
18 Nov 2026, 17:54 WIB
GlobeNewsWire
View Source
Bearish
Class action lawsuit filed against EyePoint over alleged false claims about DURAVYU drug effectiveness.

A shareholder class action lawsuit has been filed against EyePoint, Inc., claiming the company made false and misleading statements about the effectiveness and prospects of its drug DURAVYU. The lawsuit alleges that EyePoint overstated DURAVYU’s clinical, regulatory, and commercial potential, leading to investor losses. Investors who bought EyePoint shares between May 27, 2025, and August 14, 2026, and suffered losses are encouraged to contact the law firm Holzer & Holzer to discuss their legal rights. The deadline to seek lead plaintiff status is January 19, 2027.

EyePoint, Inc. faces a class action lawsuit alleging misleading statements about its drug DURAVYU. For readers following the health sector, here is Pluang's market snapshot as of Nov 18, 2026 21:51 WIB: of 150 priced health-sector US stocks, 70 rose and 75 fell. Notable movers include NTRA at USD 278.77 with a 1-day change of -3.03%, TNGX at USD 21.49 down 2.80%, and SANA at USD 1.93 up 2.66%.

More News

Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

The global pharmaceutical market is projected to grow from $1.88 trillion in 2026 to $3.20 trillion by 2035, driven mainly by obesity and oncology drugs. The U.S. market, holding 42% of the global share, faces new tariffs linked to pricing deals and ...

Bullish
53 minutes ago
LEQEMBI slows Alzheimer's progression by 76% over 3 years in real-world study of 560 patients.

LEQEMBI slows Alzheimer's progression by 76% over 3 years in real-world study of 560 patients.

A new three-year real-world study of 560 early Alzheimer's patients treated with LEQEMBI showed a 76% reduction in progression to moderate or severe dementia compared to a matched control group. Over 81% of patients remained stable or improved after ...

Market News
Bullish
53 minutes ago
Fox Factory wins seventh straight Baja 1000 and sweeps 2026 SCORE off-road championships

Fox Factory wins seventh straight Baja 1000 and sweeps 2026 SCORE off-road championships

Fox Factory Holding Corp. celebrated its seventh consecutive overall victory at the 2026 SCORE Baja 1000, with FOX Shocks and Method Race Wheels powering the winning team. The company’s equipment helped athletes sweep all four 2026 SCORE Internationa...

Market News
Bullish
53 minutes ago
Global automotive actuators market to grow to $40.3B by 2033 driven by electrification and automation

Global automotive actuators market to grow to $40.3B by 2033 driven by electrification and automation

The global automotive actuators market, valued at $29.3 billion in 2025, is projected to grow to $40.3 billion by 2033 at a CAGR of 4.4%. Growth is fueled by rising electric vehicle production, advanced safety systems, and automation technologies. As...

Market News
Bullish
53 minutes ago
TJX Companies beats Q3 sales estimates; shares jump 10% on strong international growth and holiday optimism.

TJX Companies beats Q3 sales estimates; shares jump 10% on strong international growth and holiday optimism.

The TJX Companies reported Q3 FY2027 revenue of $16 billion, beating estimates with a 5.5-6% year-over-year increase. Comparable store sales grew 4%, led by strong international segment performance, while the domestic Marmaxx group showed slower grow...

Company Fundamentals
Bullish
56 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App